Novartis' psoriasis rivals tout impressive data with next-gen treatments

Novartis ($NVS) became the first to win approval among a scrum of drugmakers with new antibody treatments for autoimmune disease, but its rivals are bounding toward the FDA with positive data of their own. At the annual American Academy of Dermatology meeting, Boehringer Ingelheim unveiled promising data on its injected treatment, while Pfizer ($PFE) heralded psoriasis results with its autoimmune drug Xeljanz. Each hopes to outpace Novartis' recently approved Cosentyx and contend with candidates from Eli Lilly ($LLY), Merck ($MRK), Johnson & Johnson ($JNJ), and partners Amgen ($AMGN) and AstraZeneca ($AZN). Story

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.